Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

Across trials, there was an average weight loss of around 15 to 17 percent after 68 weeks of treatment. Since Wegovy is prescribed in higher doses, it can be more effective than Ozempic for weight ...